Cargando…

The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense Oligonucleotides in mdx Mice

Antisense-mediated exon skipping is currently in clinical development for Duchenne muscular dystrophy (DMD) to amend the consequences of the underlying genetic defect and restore dystrophin expression. Due to turnover of compound, transcript, and protein, chronic treatment with effector molecules (a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verhaart, Ingrid E C, van Vliet-van den Dool, Laura, Sipkens, Jessica A, de Kimpe, Sjef J, Kolfschoten, Ingrid G M, van Deutekom, Judith C T, Liefaard, Lia, Ridings, Jim E, Hood, Steve R, Aartsma-Rus, Annemieke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950770/ https://www.ncbi.nlm.nih.gov/pubmed/24549299 http://dx.doi.org/10.1038/mtna.2014.1

Ejemplares similares

Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
por: Heemskerk, Hans, et al.
Publicado: (2010)

BACE1 Inhibition Using 2’-OMePS Steric Blocking Antisense Oligonucleotides
por: Chakravarthy, Madhuri, et al.
Publicado: (2019)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
por: Tanganyika-de Winter, Christa L, et al.
Publicado: (2012)

The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2012)

Nonclinical Exon Skipping Studies with 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn−/− Mice Inspired by Clinical Trial Results
por: van Putten, Maaike, et al.
Publicado: (2019)

Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP)
por: Yılmaz-Eliş, A Seda, et al.
Publicado: (2013)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
por: van Putten, Maaike, et al.
Publicado: (2014)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2007)

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
por: Veltrop, Marcel, et al.
Publicado: (2018)

Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice
por: Bizot, Flavien, et al.
Publicado: (2022)

Persistent Dystrophin Protein Restoration 90 Days after a Course of Intraperitoneally Administered Naked 2′OMePS AON and ZM2 NP-AON Complexes in mdx Mice
por: Bassi, Elena, et al.
Publicado: (2012)

7′,5′-alpha-bicyclo-DNA: new chemistry for oligonucleotide exon splicing modulation therapy
por: Evéquoz, Damien, et al.
Publicado: (2021)

Good news for the mdx mouse community: Improved dystrophin restoration after skipping mouse dystrophin exon 23
por: Aartsma-Rus, Annemieke
Publicado: (2022)

Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide
por: Evers, Melvin M., et al.
Publicado: (2011)

Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy
por: Kogelman, Bauke, et al.
Publicado: (2018)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Detailed genetic and functional analysis of the hDMDdel52/mdx mouse model
por: Yavas, Alper, et al.
Publicado: (2020)

Assessment of Behavioral Characteristics With Procedures of Minimal Human Interference in the mdx Mouse Model for Duchenne Muscular Dystrophy
por: Engelbeen, Sarah, et al.
Publicado: (2021)

Plasma lipidomic analysis shows a disease progression signature in mdx mice
por: Tsonaka, Roula, et al.
Publicado: (2021)

Generation of Embryonic Stem Cells and Mice for Duchenne Research
por: Veltrop, Marcel, et al.
Publicado: (2013)

Using a State-of-the-Art Toolbox to Evaluate Molecular and Functional Readouts of Antisense Oligonucleotide-Induced Exon Skipping in mdx Mice
por: Datson, Nicole A., et al.
Publicado: (2020)

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
por: van Vliet, Laura, et al.
Publicado: (2008)

Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy
por: van Putten, Maaike, et al.
Publicado: (2019)

The Coronavirus Pandemic and Lessons Learned in Preschools in Norway, Sweden and the United States: OMEP Policy Forum
por: Pramling Samuelsson, Ingrid, et al.
Publicado: (2020)

A modified diet does not ameliorate muscle pathology in a mouse model for Duchenne muscular dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2019)

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives
por: Synofzik, Matthis, et al.
Publicado: (2022)

A Sensitive, Reproducible and Objective Immunofluorescence Analysis Method of Dystrophin in Individual Fibers in Samples from Patients with Duchenne Muscular Dystrophy
por: Beekman, Chantal, et al.
Publicado: (2014)

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
por: Goossens, Remko, et al.
Publicado: (2023)

Induction of revertant fibres in the mdx mouse using antisense oligonucleotides
por: Fall, Abbie M, et al.
Publicado: (2006)

Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
por: van Deutekom, Judith, et al.
Publicado: (2023)

Antisense-Mediated RNA Targeting: Versatile and Expedient Genetic Manipulation in the Brain
por: Zalachoras, Ioannis, et al.
Publicado: (2011)

Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
por: Jirka, Silvana M G, et al.
Publicado: (2015)

Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor
por: Kemaladewi, Dwi U, et al.
Publicado: (2014)

Aminoglycoside Enhances the Delivery of Antisense Morpholino Oligonucleotides In Vitro and in mdx Mice
por: Wang, Mingxing, et al.
Publicado: (2019)

Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F
por: Verhaart, Ingrid E. C., et al.
Publicado: (2019)

Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review
por: Verhaart, Ingrid E. C., et al.
Publicado: (2017)

Synthesis and Antisense Properties of 2′β-F-Arabinouridine Modified Oligonucleotides with 4′-C-OMe Substituent
por: He, Xiao-Yang, et al.
Publicado: (2018)

Saponins as Natural Adjuvant for Antisense Morpholino Oligonucleotides Delivery In Vitro and in mdx Mice
por: Wang, Mingxing, et al.
Publicado: (2018)

Exon skipping for DMD
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5br9f3uvg1cfbat4ictj2hljgj